-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MT7lr+LuPr9GD1MLBr666ziGn2M2w6azAlkT5M1AcdjHEsxjRgFt6ZkWJgsyNYML QQfdJv5h7t2vtfM+GXhtNw== 0001104659-07-035757.txt : 20070504 0001104659-07-035757.hdr.sgml : 20070504 20070504090634 ACCESSION NUMBER: 0001104659-07-035757 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070430 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20070504 DATE AS OF CHANGE: 20070504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOGEN INC CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 07817902 BUSINESS ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6179952506 MAIL ADDRESS: STREET 1: 128 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 a07-13166_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 30, 2007

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts

 

0-17999

 

04-2726691

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



 

ITEM 1.01 — Entry into a Material Definitive Agreement.

On April 30, 2007, ImmunoGen, Inc. (Nasdaq: IMGN) entered into a manufacturing agreement with Società Italiana Corticosteroidi S.r.l (SICOR). Under the terms of the agreement, SICOR agreed to produce a certain number of cGMP batches of the maytansinoid derivatives DM1 and DM4 (collectively “DMx”) which are used in the production of TAP compounds. Under the terms of the agreement, ImmunoGen will pay SICOR five million Euros for these cGMP batches of DMx through completion of the contract in early 2008. The DMx produced will be used by ImmunoGen and available for sale to its collaborative partners.

2



 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ImmunoGen, Inc.

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

Date: May 4, 2007

 

/s/ Daniel M. Junius

 

 

 

 

Daniel M. Junius

 

 

 

 

Executive Vice President and Chief Financial Officer

 

 

 

3


 -----END PRIVACY-ENHANCED MESSAGE-----